Here are three updates on gastroenterology companies to note:
CellMax Life's blood-based cancer detecting test can detect adenomas with close to 90 percent accuracy and cancer at 95 percent accuracy.
Eric Berthiaume, MD, was named Providence, R.I.-based University Gastroenterology's president.
Exelixis' cabozantinib was approved for use in patients with liver cancer. The drug was already approved for thyroid and renal cancer patients.